Chronic kidney disease (CKD), a condition characterized by a gradual loss of kidney function over time, is a major public health concern, affecting approximately 10% of the global population. The main risk factors for the development and progression of CKD are diabetes, hypertension, obesity, heart disease, and metabolic abnormalities. Although the current clinical practice such as blockade of the renin–angiotensin–aldosterone system and glycaemic control in diabetes have shown some positive results for slowing the progression of kidney damage, the risk of kidney failure as well as cardiovascular morbidity and mortality in CKD patients remains very high, resulting in devastating personal and societal impacts. Hence, there is an enormous unmet need to identify efficacious and safe therapeutic strategies to mitigate CKD.
Recent advances in the past decades have revealed the possible pathophysiological mechanisms contributing to CKD such as inflammation, fibrosis, mitochondrial dysfunction, oxidative stress, and altered gut microbiota, which help to identify new targets and pathways for novel therapies. The Research Topic aims to highlight the latest preclinical and clinical studies in potential therapeutic strategies for a variety of chronic kidney diseases such as diabetic kidney disease, glomerulonephritis, hypertensive kidney disease and polycystic kidney disease. The Research Topic will provide an update of new developments in a wide range of novel treatment approaches from gene therapy to pharmacological intervention, which will offer guidance on future directions in the discovery and development of promising therapeutic options with the transnational potential to improve outcomes for CKD patients.
The current Research Topic welcomes Original Research Articles and Reviews addressing, but not limited to, the following themes:
• Gene therapy such as siRNAs, microRNAs, long-noncoding RNAs and antisense oligonucleotides-based therapy
• Novel pharmacological targets and pathways
• Stem cell-based regenerative therapy
• Non-pharmacological interventions
• Personalized therapy
• Advanced models and technologies for target validation
• New drug delivery systems
• Clinical trials of new drugs/therapies
Chronic kidney disease (CKD), a condition characterized by a gradual loss of kidney function over time, is a major public health concern, affecting approximately 10% of the global population. The main risk factors for the development and progression of CKD are diabetes, hypertension, obesity, heart disease, and metabolic abnormalities. Although the current clinical practice such as blockade of the renin–angiotensin–aldosterone system and glycaemic control in diabetes have shown some positive results for slowing the progression of kidney damage, the risk of kidney failure as well as cardiovascular morbidity and mortality in CKD patients remains very high, resulting in devastating personal and societal impacts. Hence, there is an enormous unmet need to identify efficacious and safe therapeutic strategies to mitigate CKD.
Recent advances in the past decades have revealed the possible pathophysiological mechanisms contributing to CKD such as inflammation, fibrosis, mitochondrial dysfunction, oxidative stress, and altered gut microbiota, which help to identify new targets and pathways for novel therapies. The Research Topic aims to highlight the latest preclinical and clinical studies in potential therapeutic strategies for a variety of chronic kidney diseases such as diabetic kidney disease, glomerulonephritis, hypertensive kidney disease and polycystic kidney disease. The Research Topic will provide an update of new developments in a wide range of novel treatment approaches from gene therapy to pharmacological intervention, which will offer guidance on future directions in the discovery and development of promising therapeutic options with the transnational potential to improve outcomes for CKD patients.
The current Research Topic welcomes Original Research Articles and Reviews addressing, but not limited to, the following themes:
• Gene therapy such as siRNAs, microRNAs, long-noncoding RNAs and antisense oligonucleotides-based therapy
• Novel pharmacological targets and pathways
• Stem cell-based regenerative therapy
• Non-pharmacological interventions
• Personalized therapy
• Advanced models and technologies for target validation
• New drug delivery systems
• Clinical trials of new drugs/therapies